Abbott deal puts focus squarely on pharma

There's a lot of buzz being generated by Abbott Laboratories' deal to sell a big part of its diagnostics business to GE for more than $8 billion. That deal leaves Abbott much more focused on the pharmaceutical end of the business. One particularly interesting nugget from Avery Johnson's report in the Wall Street Journal: Abbott has developed its own software program to evaluate the risk and potential returns of each new research project it undertakes. Abbott is likely to need all the help it can muster as it tries to persuade analysts that the company can improve its pipeline and create new drugs to take the place of therapies losing patent protection.

- see this press release on the deal
- read the Wall Street Journal's report (sub. req.)

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.